This page contains a complete list of all FDA analyses conducted in the Sentinel System from the start of Mini-Sentinel in 2009 to the present.
The table below is organized at the individual analysis level (e.g., Level 1, Level 2, Query Builder, protocol-based assessment, etc.). It is designed to support searches for a specific analysis.
Alternatively, the Drug Studies table groups together related analyses that FDA conducted to address a safety concern, or set of related safety concerns. The Drug Studies page also provides important background information and describes the regulatory impact.
Note: The appearance of a drug in a Sentinel study does not mean that FDA has concluded that a causal relationship exists between the drug and the health outcome of interest. Patients and healthcare providers should refer to FDA.gov for further information about drug safety.
FDA Sentinel Analyses from ARIA and Other Sentinel Data Sources
Loading...
| Title | Medical Product | Outcomes | Date |
|---|---|---|---|
| Characterization of Cannabis-Derived Product Users in the National Patient-Centered Clinical Research Network (PCORnet): A Descriptive Analysis | cannabis-derived products
|
||
| Risk of Non-Cardiac Congenital Malformations Following Armodafinil or Modafinil Use: A Propensity Score Matched Analysis | armodafinil, modafinil
|
non-cardiac congenital malformations |
|
| Utilization of Drugs with Approved Risk Evaluation and Mitigation Strategies (REMS) that Employ Elements to Assure Safe Use (ETASU): A Descriptive Analysis | alosetron, alvimopan, clozapine, collagenase clostridium histolyticum, denosumab, eculizumab, idelalisib, isotretinoin, lenalidomide, mifepristone, mycophenolate, natalizumab, olanzapine extended release, panobinostat, phentermine/topiramate, pomalidomide, romiplostim, teduglutide, testosterone undecanoate, vigabatrin
|
||
| Racial and Ethnic Differences in COVID-19 Treatment and Mortality in TriNetX: A Descriptive Analysis | |||
| Utilization, Dispensing, and Coding Patterns of Biologics and Biosimilars in the Sentinel Distributed Database: A Descriptive Analysis | Neulasta (pegfilgrastim), Neupogen (filgrastim), Remicade (infliximab)
|
biosimilar use |
|
| COVID-19 Hospitalization and Severe COVID-19 Infection Following Proton Pump Inhibitor (PPI) Use in Patients with Gastroesophageal Reflux Disease (GERD): An Inverse Probability of Treatment Weighting Analysis | proton pump inhibitors
|
COVID-19 hospitalization , Severe COVID-19 |
|
| Characterization of Use of Biologics and Biosimilars in the Sentinel Distributed Database: A Descriptive Analysis | Neupogen (filgrastim), Remicade (infliximab)
|
biosimilar use |
|
| Utilization of Ibrexafungerp in Pregnant Patients: A Descriptive Analysis | ibrexafungerp
|
||
| Utilization of Products for the Development of the Pregnancy Safety Study Framework Among Mothers Linked to Live-Birth Deliveries in the Mother-Infant Linkage Table: A Descriptive Analysis | products for the development of the pregnancy safety study framework
|
use in pregnancy |
|
| Utilization of Products for the Development of the Pregnancy Safety Study Framework Among Mothers with Live-Birth Deliveries: A Descriptive Analysis | products for the development of the pregnancy safety study framework
|
use in pregnancy |
|
| Baloxavir and Oseltamivir Utilization: A Descriptive Analysis | baloxavir, oseltamivir
|
||
| Bevacizumab and Other Cancer Medication Use in Pregnant Patients: A Descriptive Analysis | bevacizumab, pegaptanib, ranibizumab, verteporfin
|
||
| Incident Utilization of Allopurinol, Hydralazine, and Propylthiouracil: A Descriptive Analysis | allopurinol, hydralazine, propylthiouracil
|
||
| Incident Utilization Patterns of Obesity Drugs: A Descriptive Analysis | obesity drugs
|
||
| Utilization and Switching Patterns of Mixed Amphetamine Salt (MAS) Products in Patients with Attention Deficit Hyperactivity Disorder (ADHD) and Narcolepsy: A Descriptive Analysis | mixed amphetamine salts
|
switching patterns |
|
| Utilization of Beta Blockers in the Pediatric Population: An Updated Descriptive Analysis | beta blockers
|
||
| Utilization of Beta Blockers in the Pediatric Population: A Descriptive Analysis | beta blockers
|
||
| Characterization of Cannabis-Derived Product Users in TriNetX: Four Descriptive Analyses | cannabis-derived products
|
||
| Baricitinib or Tocilizumab Use in Hospitalized Patients with a COVID-19 Diagnosis: A Descriptive Analysis | baricitinib, tocilizumab
|
emergency use authorization , utilization |
|
| Prevalence and Characterization of Pharmacogenetic Testing Healthcare Common Procedure Coding System (HCPCS) Procedure Codes in the Mini-Sentinel Distributed Database (MSDD): A Descriptive Analysis | pharmacogenetic testing
|
||
| Dupixent (Dupilumab) Utilization Patterns: A Descriptive Analysis | dupilumab dupixent
|
||
| Alosetron and Eluxadoline Use: A Descriptive Analysis | alosetron, eluxadoline
|
||
| Renal Cell Carcinoma Following Canagliflozin Use in Patients with Type 2 Diabetes: A Descriptive Analysis | canagliflozin
|
renal cell carcinoma |
|
| Outcome Monitoring Following Erenumab Use: A Signal Identification Analysis | erenumab
|
||
| Mortality Following Long-Acting Injectable Antipsychotics Use in Patients with Dementia: An Inverse Probability of Treatment Weighting Analysis Retrospective Inferential |
long-acting injectable antipsychotics
|
mortality |
|
| Biologics Use in Adults with Ulcerative Colitis: A Descriptive Analysis | adalimumab, golimumab, infliximab, vedolizumab
|
||
| Ischemic Colitis Following Alosetron Use: A Descriptive Analysis | alosetron
|
ischemic colitis |
|
| Utilization and Switching Patterns of Inhaled Corticosteroid/Long Acting Beta Agonist and Advair Diskus in Patients with Asthma or Chronic Obstructive Pulmonary Disease: A Descriptive Analysis | Advair Diskus, fluticasone salmeterol
|
brand to generic switching |
|
| Brand to Generic Switching Patterns Among Advair Diskus Users with Asthma or Chronic Obstructive Pulmonary Disease (COPD): A Descriptive Analysis | Advair Diskus, fluticasone salmeterol
|
brand to generic switching |
|
| Insulin Coding Practices: A Descriptive Analysis | insulin
|
||
| Angioedema Following Sacubitril/Valsartan Use in Patients with Heart Failure: An Updated Propensity Score Matched Analysis | sacubitril/valsartan
|
angioedema |
|
| Angioedema Following Sacubitril/Valsartan Use in Patients with Heart Failure: A Propensity Score Analysis | sacubitril/valsartan
|
angioedema |
|
| Use of Gonadotropin-Releasing Hormone (GnRH) Agonists in Patients with Gender Dysphoria: A Descriptive Analysis | gonadotropin-releasing hormone agonists
|
duration of use |
|
| Utilization of Select Products for Migraine Treatment and Prevention: A Descriptive Analysis | eptinezumab, erenumab-aooe, fremanezumab, galcanezumab, rimegepant, ubrogepant
|
||
| Utilization of Select Biological Products: A Descriptive Analysis | Avastin (bevacizumab), Epogen (epoetin alfa), Inflectra (infliximab-dyyb), Mvasi (bevacizumab-awwb), Neupogen (filgrastim), Remicade (infliximab), Renflexis (infliximab-abda), Retacrit (epoetin alfa-epbx), Zarxio (filgrastim-sndz), Zirabev (bevacizumab-bvzr)
|
||
| Outcome Monitoring Following Zarxio Use: An Updated Signal Identification Analysis | Zarxio (filgrastim-sndz)
|
||
| Congenital Malformations Observed in the Mother’s or Linked Infant’s Records Following Fingolimod Use During Pregnancy: A Descriptive Analysis | fingolimod
|
all congenital malformations , congenital cardiac malformations (primary) , congenital urinary malformations (primary) |
|
| Congenital Malformations Observed in the Mother’s Records Following Fingolimod Use During Pregnancy: A Descriptive Analysis | fingolimod
|
all congenital malformations , congenital cardiac malformations (primary) , congenital urinary malformations (primary) |
|
| Cardiovascular Outcomes Following Percutaneous Transluminal Septal Myocardial Ablation (PTSMA) Procedures: A Descriptive Analysis | dehydrated alcohol
|
atrioventricular block , heart failure , permanent pacemaker placement , septal myectomy , ventricular arrhythmia |
|
| Cardiovascular Outcomes Following Percutaneous Transluminal Septal Myocardial Ablation (PTSMA) Procedures: An Updated Descriptive Analysis | dehydrated alcohol
|
atrioventricular block , heart failure , myocardial infarction , permanent pacemaker placement , septal myectomy , ventricular arrhythmia |
|
| Characterization of Patients and Encounters in the TriNetX Live USA Network: A Descriptive Analysis | |||
| Identifying Potential Risk Factors for Respiratory Failure: A Descriptive Analysis | acute respiratory failure |
||
| Exploring Claims-Based Definitions of, and Characterizing Patients with, Respiratory Failure: A Descriptive Analysis | acute respiratory failure |
||
| Utilization of Ixekizumab in Pregnant Patients: A Descriptive Analysis | ixekizumab
|
||
| Outcome Monitoring Following Ozempic Use in Patients with Type 2 Diabetes: A Signal Identification Analysis | Ozempic (semaglutide)
|
||
| Outcome Monitoring Following Zarxio Use: A Signal Identification Analysis | Zarxio (filgrastim-sndz)
|
||
| Utilization of Ibrexafungerp in Pregnant Patients: A Descriptive Analysis in TriNetX | ibrexafungerp
|
||
| Fractures Following Leuprolide Acetate Use: A Multiple Factor Matched Analysis | leuprolide acetate
|
any fracture , hip replacement , major fracture (primary) , temporomandibular joint replacement |
|
| Fractures Following Leuprolide Acetate Use: A Multiple Factor Matched Analysis (A Follow-up to a Previous Analysis) | leuprolide acetate
|
any fracture , hip replacement , major fracture (primary) , temporomandibular joint replacement |
|
| Comparative Effectiveness of Azithromycin Relative to Roflumilast in Individuals With Uncontrolled Chronic Obstructive Pulmonary Disease Despite Triple Inhaled Therapy | azithromycin, roflumilast
|
hospitalization and death |
|
| Use of Monoclonal Antibodies (mAbs) Under an Emergency Use Authorization (EUA) in Patients with COVID-19 Diagnosis: An Updated Descriptive Analysis | bamlanivimab, bamlanivimab etesevimab, casirivimab imdevimab
|
utilization |
|
| Differences in COVID-19 Testing, Positivity, Hospitalization, and Mortality by Race and Ethnicity in the Sentinel Distributed Database: A Descriptive Analysis | |||
| Utilization of Obesity Drugs: A Descriptive Analysis | obesity drugs
|
||
| Hospitalization and Anaphylaxis Following Monoclonal Antibodies (mAb) Use in Patients with COVID-19: A Descriptive Analysis | bamlanivimab, bamlanivimab etesevimab, casirivimab imdevimab, sotrovimab
|
anaphylaxis , hospitalization |
|
| Utilization of Sodium Glucose Co-Transporter-2 (SGLT-2) Inhibitor Drugs: A Descriptive Analysis | obesity drugs, sodium-glucose co-transporter-2 (SGLT-2) inhibitor
|
||
| Seizures Following Gadolinium-Based Contrast Agents Exposure: A Self-Controlled Risk Interval Analysis | gadolinium-based contrast agents (GBCA)
|
seizure |
|
| Tacrolimus Use in Patients Following Liver or Kidney Transplants: A Descriptive Analysis | tacrolimus
|
||
| Use of Monoclonal Antibodies (mAbs) Under an Emergency Use Authorization (EUA) in Patients with COVID-19 Diagnosis: A Descriptive Analysis | bamlanivimab, bamlanivimab etesevimab, casirivimab imdevimab
|
utilization |
|
| Count and Duration of Follow up of New-Onset Cancer: An Updated Descriptive Analysis | duration of follow up |
||
| Characterizing Pregnant Women With and Without Evidence of Heart Failure and Non-Pregnant Women With Heart Failure: A Propensity Score Matched Analysis | |||
| Bamlanivimab, Bamlanivimab and Etesevimab, and Casirivimab-Imdevimab Use in Patients with COVID-19: A Descriptive Analysis | bamlanivimab, bamlanivimab etesevimab, casirivimab imdevimab
|
utilization |
|
| Outpatient Corticosteroid Use in Patients With COVID-19: An Updated Descriptive Analysis | corticosteroids
|
||
| Outpatient Corticosteroid Use in Patients With COVID-19: A Descriptive Analysis | corticosteroids
|
||
| Serious Infection Following Ustekinumab Use in Patients with Crohn’s Disease or Ulcerative Colitis: A Descriptive Analysis | ustekinumab
|
serious infection (Crohn’s disease) , serious infection (ulcerative colitis) |
|
| Characterization of Pediatric Demographics and Enrollment in the Sentinel Distributed Database: A Descriptive Analysis | |||
| Death Data Exploration: A Descriptive Analysis | |||
| Thromboembolic Stroke, Major Extracranial Bleeding, Gastrointestinal Bleeding, and Intracranial Hemorrhage following Direct Oral Anticoagulant Use: An Inverse Probability of Treatment Weighting Analysis | apixaban, dabigatran, rivaroxaban
|
gastrointestinal bleeding , intracranial hemorrhage , major extracranial bleeding , thromboembolic stroke |
|
| Incidence and Prevalence of Confounding Variables Over Time in the Sentinel Distributed Database (SDD): A Descriptive Analysis | |||
| Duration of Follow Up for New Molecular Entities Approved in 2018: A Descriptive Analysis | new molecular entities (NMEs)
|
||
| Counts and Characteristics of Individuals With Drug-Device Combination Use: A Descriptive Analysis | drug device combinations
|
||
| Utilization of Brodalumab: A Descriptive Analysis | brodalumab
|
||
| Estimated Prevalence of Glomerular Diseases: An Updated Descriptive Analysis | glomerular diseases |
||
| Estimated Prevalence of Glomerular Diseases: A Descriptive Analysis | glomerular diseases |
||
| Hydroxyurea Use Among Patients with Sickle Cell Disease (SCD): A Descriptive Analysis | hydroxyurea
|
||
| Epidiolex (prescription cannabidiol) Utilization Patterns: A Descriptive Analysis | Epidiolex (prescription cannabidiol)
|
||
| Valganciclovir Use in Children with Congenital Cytomegalovirus Disease (cCMV) or Cytomegalovirus (CMV) Infection: A Descriptive Analysis | valganciclovir
|
congenital cmv |
|
| Incident and Prevalent Use of Loop Diuretics: A Descriptive Analysis | loop diuretics
|
||
| Human Epidermal Growth Factor Receptor 2 (HER2) Antagonist Use in Patients with Live Birth Deliveries: A Descriptive Analysis | HER2 antagonists
|
||
| Drug Utilization Over Time for Six Drug Classes | ace inhibitors, beta blockers, granulocyte colony-stimulating factor (GC-SF), intravenous (IV) iron, statins, tumor necrosis factor (TNF) alpha inhibitor
|
||
| Mometasone Furoate Sinus Implant Use in Patients with Nasal Polyps: A Descriptive Analysis | mometasone sinus implant
|
||
| Incidence and Prevalence of N-Nitrosodimethylamine (NDMA) and N-Nitrosodiethylamine (NDEA) Contaminated Valsartan Use: A Descriptive Analysis | valsartan
|
||
| Bleeding Events and Venous Thromboembolism (VTE) following Enoxaparin Use: A Descriptive Analysis | enoxaparin
|
hospitalized bleeding , major bleeding , venous thromboembolism (VTE) |
|
| Tofacitinib, Disease-Modifying Anti-Rheumatic Drugs (DMARDs) and Tumor Necrosis Factor Inhibitors (TNFi) Use: A Descriptive Analysis | disease-modifying anti-rheumatic drugs (DMARDs), tofacitinib, tumor necrosis factor inhibitors (TNFi)
|
||
| N‐nitrosodimethylamine (NDMA)‐Contaminated and Non‐NDMA‐Contaminated Valsartan Use: A Descriptive Analysis | valsartan
|
||
| Duration of Follow Up for New Molecular Entities Approved in 2019: A Descriptive Analysis | new molecular entities (NMEs)
|
||
| Duration of Follow Up for New Molecular Entities Approved in 2017: An Updated Descriptive Analysis | new molecular entities (NMEs)
|
||
| Intentional Self-Harm and Hospitalized Depression Following Sertraline Use: A Propensity Score Matched Analysis | sertraline
|
hospitalized depression , intentional self-harm |
|
| Intentional Self-Harm and Hospitalized Depression Following Sertraline Use: A Propensity Score Matched Analysis (A Follow-up to a Previous Analysis) | sertraline
|
hospitalized depression , intentional self-harm |
|
| Racial Differences in COVID-19 Outcomes (2020-2021) | Critical COVID-19 , death , hospitalization with COVID-19 |
||
| Use of Multiple Sclerosis Drugs Among Pregnant Women with Live-Birth Deliveries: A Descriptive Analysis | alemtuzumab, cladribine, dalfampridine, dimethyl fumarate, diroximel fumarate, fingolimod, glatiramer acetate, interferon beta-1A, interferon beta-1B, mitoxantrone, natalizumab, ocrelizumab, peginterferon beta-1a, siponimod, teriflunomide
|
||
| Oral Metoclopramide Use: A Descriptive Analysis | metoclopramide
|
||
| Utilization of Drugs with Approved Risk Evaluation and Mitigation Strategies (REMS) that Employ Elements to Assure Safe Use (ETASU) | drugs with REMS that employ ETASU
|
||
| Duration of Follow Up for New Molecular Entities Approved in 2017: A Descriptive Analysis | new molecular entities (NMEs)
|
||
| Brand and Generic Tacrolimus Use following Kidney, Heart, and Liver Transplants: A Descriptive Analysis | tacrolimus
|
||
| Incidence Rate of Severe Uterine Bleeding Among New Users of Oral Anticoagulants: A Descriptive Analysis | apixaban, dabigatran, oral anticoagulant, rivaroxaban, warfarin
|
severe uterine bleed |
|
| Utilization of Sacubitril/Valsartan: A Descriptive Analysis | sacubitril/valsartan
|
||
| Patterns in Insulin Product Use and Billing Codes: A Descriptive Analysis | insulin
|
||
| Duration of Follow Up for New Molecular Entities Approved in 2005, 2006, and 2007 | new molecular entities (NMEs)
|
||
| Duration of Follow Up for New Molecular Entities Approved in 2011 | new molecular entities (NMEs)
|
||
| Duration of Follow Up for New Molecular Entities Approved in 2008 and 2009 | new molecular entities (NMEs)
|
||
| Duration of Follow Up for New Molecular Entities Approved in 2010, 2012, and 2013 | new molecular entities (NMEs)
|
||
| Duration of Follow Up for New Molecular Entities Approved in 2014 and 2015 | new molecular entities (NMEs)
|
||
| Duration of Follow Up for New Molecular Entities Approved in 2016 | new molecular entities (NMEs)
|
||
| Lymphoma Risk following Guselkumab, Risankizumab, or Tildrakizumab Use: A Descriptive Analysis | guselkumab, risankizumab, tildrakizumab
|
lymphoma |
|
| Angioedema following Dipeptidyl Peptidase IV (DPP IV) Inhibitors and Angiotensin Converting Enzyme (ACE) Inhibitors Use: A Descriptive Analysis | angiotensin-converting enzyme (ACE) inhibitor, dipeptidyl peptidase-IV (DPP-IV) inhibitor
|
angioedema |
|
| Venous and Arterial Thromboembolism among New Users of NuvaRing and Other Combined Hormonal Contraceptives: A Descriptive Analysis | combined hormonal contraceptives (CHCs), ethinyl estradiol (EE), NuvaRing
|
arterial thromboembolism (ATE) , venous thromboembolism (VTE) |
|
| Counts of Individuals in the Sentinel Distributed Database | |||
| Characterization of Mothers in the Mother-Infant Linkage Table in the Sentinel Distributed Database: A Descriptive Analysis | |||
| Pregnancy among Women with Heart Failure: A Descriptive Analysis | pregnancy |
||
| Serious Infections among Immunocompromised Health Plan Members | serious infection |
||
| Cutaneous Small-Vessel Vasculitis following Dabigatran, Rivaroxaban, and Apixaban Use in Patients with Atrial Fibrillation: A Propensity Score Matched Analysis | apixaban, dabigatran, direct oral anticoagulant (DOAC), rivaroxaban, warfarin
|
cutaneous small-vessel vasculitis |
|
| Direct Oral Anticoagulants (DOACs), Warfarin, Allopurinol, or Propylthiouracil Use in Patients with Cutaneous Small-Vessel Vasculitis: A Descriptive Analysis | allopurinol, direct oral anticoagulant (DOAC), propylthiouracil, warfarin
|
cutaneous small-vessel vasculitis |
|
| Prevalent and Incident Drug Use in a Pediatric Population: A Descriptive Analysis | acetaminophen with codeine, acyclovir, acyclovir sodium, albuterol, albuterol sulfate, levalbuterol HCL, levalbuterol tartrate, nitazoxanide, nizatidine, oxycodone HCL, sucralfate
|
||
| Abacavir, Carbamazepine, Clopidogrel, and Phenytoin Use: A Descriptive Analysis | abacavir, carbamazepine, clopidogrel, phenytoin
|
||
| Incidence of Acute Respiratory Failure (ARF) following Trimethoprim-Sulfamethoxazole (TMP-SMX) Use: A Descriptive Analysis | trimethoprim-sulfamethoxazole
|
acute respiratory failure |
|
| Thrombotic Events and Death in Inpatient-Identified COVID-19 Patients | thrombotic events |
||
| Thrombotic Events in COVID-19 Patients Not Requiring Hospitalization at the Time of Diagnosis | thrombotic events |
||
| Ustekinumab Dispensing Patterns: A Descriptive Analysis | ustekinumab
|
||
| Risk of Cardiac Congenital Malformations Following Armodafinil or Modafinil Use: A Propensity Score Matched Analysis | armodafinil, modafinil
|
cardiac congenital malformations |
|
| Risk of Cardiac Congenital Malformations Following Armodafinil or Modafinil Use: A Descriptive Analysis | armodafinil, modafinil
|
cardiac congenital malformations |
|
| Counts of Individuals with Gout Using Urate-Lowering Therapy (ULT) and Switching between ULT Products: A Descriptive Analysis | allopurinol, febuxostat
|
||
| Incidence of Severe Uterine Bleed Following Novel Oral Anticoagulants Use: A Descriptive Analysis | apixaban, dabigatran, rivaroxaban, warfarin
|
severe uterine bleed |
|
| Mini-Sentinel: Diabetic Ketoacidosis following Sodium-Glucose Cotransporter-2 (SGLT-2) Inhibitors, Sulfonylureas, Saxagliptin, and Sitagliptin Use: A Descriptive Analysis | saxagliptin, sitagliptin, sodium-glucose cotransporter-2 (SGLT-2) inhibitor, sulfonylurea
|
diabetic ketoacidosis |
|
| Thromboembolic Stroke, Intracranial Hemorrhage, Gastrointestinal Bleeding, and Major Extracranial Bleeding following Dabigatran, Rivaroxaban, and Apixaban Use in Patients with Atrial Fibrillation: A Propensity Score Matched Analysis | apixaban, dabigatran, non-vitamin K antagonist oral anticoagulants, rivaroxaban
|
gastrointestinal bleeding , intracranial hemorrhage , major extracranial bleeding , thromboembolic stroke |
|
| Wrong Frequency Errors with Low Dose Oral Methotrexate | methotrexate
|
||
| Factors Related to the Assignment of Sodium Glucose Cotransporter-2 Inhibitors (SGLT-2i) versus Dipeptidyl Peptidase-4 Inhibitors (DPP-4i) | sodium-glucose cotransporter-2 (SGLT-2) inhibitor
|
factors for treatment assignment |
|
| Frequency of Percutaneous Transluminal Septal Myocardial Ablation (PTSMA) and Estimated Incidence Rates of Post-PTSMA Cardiovascular Outcomes: A Descriptive Analysis | percutaneous transluminal septal myocardial ablation |
||
| Acute Myocardial Infarction and Heart Failure following Saxagliptin or Sitagliptin Use: A Propensity Score Matched Analysis | long-acting insulin, pioglitazone, saxagliptin, second-generation sulfonylurea, sitagliptin
|
acute myocardial infarction (AMI) , heart failure |
|
| Stroke, Intracranial Hemorrhage, and Bleeding following Dabigatran, Rivaroxaban, and Apixaban Use in Patients Aged 65 or Older: A Propensity Score Matched Analysis | apixaban, dabigatran, rivaroxaban
|
bleeding event , intracranial hemorrhage , stroke |
|
| Cutaneous Small-Vessel Vasculitis following Direct Oral Anticoagulants (DOACs), Warfarin, or Allopurinol Use in Patients with Atrial Fibrillation: A Descriptive Analysis | allopurinol, direct oral anticoagulant (DOAC), warfarin
|
cutaneous small-vessel vasculitis |
|
| Same Day Seizures following Gadolinium Based Contrast Agents: A Self-Controlled Risk Interval Analysis | gadolinium-based contrast agent (GBCA)
|
seizure |
|
| Ranitidine Drug Utilization Patterns | ranitidine
|
||
| Intravenous (IV) Iron Utilization Among Pregnant Women | intravenous (IV) iron
|
||
| Algorithms to Estimate Start of Pregnancy Using In-Vitro Fertilization (IVF), Intrauterine Insemination (IUI), and Select Prenatal Tests among Pregnancies Resulting in a Live-Born Delivery | |||
| Mini-Sentinel: Availability of International Normalized Ratio (INR) Laboratory Test Values and INR Test Procedures among New Warfarin Users | warfarin
|
||
| Spironolactone Use in Patients with Reduced Ejection Fraction Heart Failure (HFrEF) or Preserved Ejection Fraction Heart Failure (HFpEF) | spironolactone
|
||
| Sacubitril/Valsartan, Angiotensin-Converting Enzyme (ACE) Inhibitors, and Other Angiotensin II Receptor Blockers (ARBs) Use in Patients with Heart Failure | angiotensin II receptor blocker (ARB), angiotensin-converting enzyme (ACE) inhibitor, sacubitril/valsartan
|
||
| Mini-Sentinel: Switching Between Generic and Brand Clonazepam | clonazepam
|
||
| Glaucoma, Cataracts, Diminished Visual Acuity, and Nasal Septal Perforation following Mometasone Sinus Implant Use in Patients with Nasal Polyposis: A Descriptive Analysis | cataracts , diminished visual acuity , glaucoma , nasal septal perforation |
||
| Hypertension in Pediatric Patients: A Descriptive Analysis | hypertension |
||
| Use of Typical and Atypical Antipsychotics Among Infants | antipsychotic, atypical antipsychotic, typical antipsychotic
|
||
| Characterization of SGLT-2 Inhibitor Users in the Patient-Centered Clinical Research Network (PCORnet) | sitagliptin, sodium-glucose cotransporter-2 (SGLT-2) inhibitor
|
||
| Non-Melanoma Skin Cancer following Hydrochlorothiazide Use: A Propensity Score Matched Analysis | hydrochlorothiazide (HCTZ)
|
non-melanoma skin cancer |
|
| Total Enrollment with Medical and Drug Coverage | |||
| Trends in Penicillin Allergy Testing | penicillin allergy test
|
||
| Time Until Guillain-Barré Syndrome or Bell's Palsy Diagnosis following Initiation of Checkpoint Inhibitor Treatment | atezolizumab, avelumab, durvalumab, ipilimumab, nivolumab, pembrolizumab
|
Bell’s palsy , Guillain-Barré syndrome |
|
| Prenatal Tests in Women with Potential Stillbirths | prenatal tests
|
stillbirth |
|
| Concurrent Use of Ticagrelor with Atorvastatin or Rosuvastatin | atorvastatin, rosuvastatin, ticagrelor
|
||
| Duration of Follow-up for Individuals with Chronic Conditions | Alzheimer's disease , acquired hypothyroidism , acute myocardial infarction (AMI) , anemia , asthma , atrial fibrillation , benign prostatic hyperplasia , breast cancer , bronchiectasis , chronic conditions , chronic kidney disease (CKD) , chronic obstructive pulmonary disease , colorectal cancer , depression , diabetes , endometrial cancer , glaucoma , heart failure , hyperlipidemia , hypertension , ischemic heart disease , lung cancer , osteoarthritis , osteoporosis , prostate cancer , rheumatoid arthritis , stroke , transient ischemic attack (TIA) |
||
| Use of Metoclopramide among Patients with Diabetic Gastroparesis and Type 2 Diabetes | metoclopramide HCL
|
duration of use |
|
| Hydroxyurea Use in Patients with Sickle Cell Anemia | hydroxyurea
|
sickle cell anemia , use by indication |
|
| Mini-Sentinel: Summary of Antidiabetic Agent Use During Pregnancy | alpha-glucosidase inhibitor, amylin analog, biguanide, dipeptidyl peptidase-4 (DPP-4) inhibitor, glucagon-like peptide-1 (GLP-1) receptor agonist, injectable insulin, meglitinide analog, sulfonylurea, thiazolidinedione
|
exposure in pregnancy |
|
| Epidemiology of Pediatric Respiratory Syncytial Virus-Associated Illness in FDA’s Sentinel System | respiratory syncytial virus (RSV) , respiratory syncytial virus-associated illness |
||
| Estimating Optimal Quantities for Initial Opioid Analgesic Prescriptions for Acute Pain Conditions Presenting to Surgical Settings | opioid analgesic
|
drug refill probability |
|
| Respiratory Syncytial Virus in a Pediatric Population | respiratory syncytial virus (RSV) |
||
| Hydroxyprogesterone Caproate and Progesterone Use During Pregnancy | hydroxyprogesterone caproate, progesterone
|
exposure in pregnancy |
|
| Neuropsychiatric Events Following Montelukast Use: A Propensity Score Matched Analysis | montelukast
|
inpatient depressive disorder , outpatient depressive disorder , self-harm , suicide |
|
| Multiple Sclerosis Relapses among Copaxone, Glatopa, Gilenya, and Glatiramer Users | Copaxone, Gilenya, glatiramer, Glatopa
|
multiple sclerosis relapse |
|
| Cutaneous Small Vessel Vasculitis and Acute Kidney Injury Following Direct-Acting Oral Anticoagulant Use | direct oral anticoagulant (DOAC)
|
acute kidney injury , cutaneous small-vessel vasculitis |
|
| Sinus Stents with Mometasone and Diminished Visual Acuity | intranasal steroid, mometasone, oral steroid, sinus stent
|
blindness , cataract surgery , cataracts , diminished visual acuity , glaucoma |
|
| Non-Melanoma Skin Cancer following Hydrochlorothiazide Use | bendroflumethiazide (BFMTZ), chlorothiazide (CTZ), hydrochlorothiazide (HCTZ)
|
non-melanoma skin cancer |
|
| Use of Angiotensin-Converting Enzyme (ACE) Inhibitors and Angiotensin Receptor Blockers (ARB) in a Pediatric Population | angiotensin receptor blocker, angiotensin-converting enzyme (ACE) inhibitor
|
||
| Utilization Patterns of Qsymia (Phentermine/Topiramate) | phentermine HCl, phentermine/topiramate, Qsymia, topiramate
|
||
| Use of Higher Dosage Strength Oral and Transmucosal Opioid Analgesics | higher dosage strength opioid analgesic, lower dosage strength opioid analgesic, opioid analgesic, oral opioid analgesic, transdermal opioid analgesic, transmucosal opioid analgesic
|
||
| Ischemic Stroke, Intracranial Hemorrhage, and Gastrointestinal Hemorrhage Among New Users of Apixaban and Warfarin | apixaban, warfarin
|
gastrointestinal hemorrhage , intracranial hemorrhage , ischemic stroke |
|
| Use of Korlym and Mifeprex (Mifepristone) | Korlym, Mifeprex, mifepristone
|
||
| Antiemetic Use During Pregnancy | doxylamine, granisetron, metoclopramide HCL, netupitant/palonosetron HCl, ondansetron, palonosetron, prochlorperazine, promethazine HCl, succinate/pyridoxine HCl
|
exposure in pregnancy |
|
| Use of Valsartan, Angiotensin II Receptor Blockers (ARB), and Angiotensin-Converting Enzyme (ACE) Inhibitors | angiotensin II receptor blocker (ARB), angiotensin-converting enzyme (ACE) inhibitor, azilsartan medoxomil, candesartan, eprosartan, irbesartan, losartan, olmesartan, telmisartan, valsartan
|
||
| New Users of Oral Bisphosphonates | bisphosphonate
|
||
| Neuropsychiatric Events following Montelukast Use | inhaled corticosteroid, montelukast, nasal corticosteroid, zafirlukast
|
neuropsychiatric event , psychotropic medication use , suicide |
|
| Duration of Use Among New Users of Hydrochlorothiazide (HCTZ), Angiotensin-Converting Enzyme Inhibitors (ACEIs), and Angiotensin II Receptor Blockers (ARBs) | angiotensin II receptor blocker (ARB), angiotensin-converting enzyme (ACE) inhibitor, hydrochlorothiazide (HCTZ)
|
||
| Severe Uterine Bleed Following Novel Oral Anticoagulants Use: A Propensity Score Analysis | apixaban, dabigatran, novel oral anticoagulant (NOAC), rivaroxaban, warfarin
|
severe uterine bleed |
|
| Leuprolide Acetate Use Among Patients with Central Precocious Puberty | leuprolide acetate
|
central precocious puberty |
|
| Gadolinium-Based Contrast Agents (GBCAs) Use in Pregnancy | gadolinium-based contrast agent (GBCA)
|
exposure in pregnancy |
|
| Duration of Follow-Up and Treatment for Non-Insulin Antidiabetic Drugs | non-insulin antidiabetics
|
||
| Dolutegravir Use During Pregnancy | dolutegravir
|
exposure in pregnancy |
|
| Acute Myocardial Infarction and Stroke Among Patients with Testosterone-Related Indications | testosterone
|
acute myocardial infarction (AMI) , stroke |
|
| Brintellix and Brilinta Medication Errors due to Name Confusion | Brilinta, Brintellix
|
medication error |
|
| Characteristics of Gout Patients and Use of Urate-Lowering Therapies | urate-lowering therapies
|
||
| SGLT-2 Inhibitor Use and Incidence of Diabetic Ketoacidosis in Patients with Type 1 Diabetes Mellitus | canagliflozin, dapagliflozin, empagliflozin, sitagliptin, sodium-glucose cotransporter-2 (SGLT-2) inhibitor
|
diabetic ketoacidosis |
|
| Stroke, Gastrointestinal Bleeding, and Intracranial Hemorrhage Following Apixaban or Warfarin Use in Patients with Non-Valvular Atrial Fibrillation: A Propensity Score Matched Analysis | apixaban
|
gastrointestinal (GI) bleed , intracranial hemorrhage , stroke |
|
| Optimal Initial Length of Opioid Prescription | opioid analgesic
|
||
| Seizure Following Ranolazine Use | Ranexa, ranolazine
|
seizure |
|
| Use of Multiple Sclerosis Drugs Among Pregnant Women | alemtuzumab, daclizumab, dalfampridine, dimethyl fumarate, fingolimod, glatiramer acetate, interferon beta-1A, interferon beta-1A/albumin, interferon beta-1B, mitoxantrone, natalizumab, peginterferon beta-1a, teriflunomide
|
pregnancy |
|
| Pulmonary Arterial Hypertension and Interstitial Lung Disease Events Among Interleukin Inhibitor Users | interleukin-1/-6 inhibitor
|
interstitial lung disease , pulmonary arterial hypertension |
|
| Duration of Use for Teriparatide | teriparatide
|
||
| Quantifying Prevalence and Mortality Associated with Neonatal Enteroviral Sepsis (NES) Using Inpatient Data in FDA’s Sentinel System | neonatal enteroviral sepsis (NES) |
||
| COPD, Asthma, and Respiratory Disease Effectiveness (CARE) For 21st Century Cures: Feasibility Assessments for Comparative Effectiveness Studies | asthma , chronic obstructive pulmonary disease |
||
| Counts and Proportions of New Users of Fentanyl Transdermal System with Evidence of Prior Opioid Tolerance | fentanyl transdermal system
|
||
| Phosphodiesterase Type 5 (PDE-5) Inhibitor Utilization Among Women | phosphodiesterase type 5 (PDE5) inhibitor
|
||
| Sofosbuvir and Amiodarone Use and Bradycardia or Pacemaker Insertion | amiodarone, sofosbuvir
|
bradycardia , pacemaker insertion |
|
| Algorithms Evaluating Dabigatran Use and Acute Myocardial Infarction Compared with Warfarin | dabigatran, warfarin
|
acute myocardial infarction (AMI) |
|
| New Pediatric Users of Leuprolide Acetate | leuprolide acetate
|
||
| Use of Dabigatran and Intracranial Hemorrhage, Gastrointestinal Hemorrhage, Ischemic Stroke, and Acute Myocardial Infarction | dabigatran
|
acute myocardial infarction (AMI) , gastrointestinal hemorrhage , intracranial hemorrhage , ischemic stroke |
|
| Prevalence and Incidence of Progressive Multifocal Leukoencephalopathy (PML), Clostridium Difficile, and Cytomegalovirus (CMV) Diagnoses | clostridium difficile , cytomegalovirus (CMV) , progressive multifocal leukoencephalopathy (PML) |
||
| Incident Use of Selective Serotonin Reuptake Inhibitor Antidepressants | selective serotonin reuptake inhibitor (SSRI)
|
||
| Identifying Suicide Codes in the Sentinel Distributed Database (SDD) | suicide |
||
| Clostridium difficile Infection Following Use of Vancomycin, Fidaxomicin, or Metronidzaole | fidaxomicin, metronidazole, vancomycin
|
clostridium difficile |
|
| Availability of International Normalized Ratio (INR) Laboratory Test Values and Test Procedures Among Warfarin Users | warfarin
|
||
| Warfarin Use Followed by International Normalized Ratio (INR) Lab Codes | warfarin
|
||
| Top Ten Causes of Death | |||
| Prevalent and Incident Use of Fingolimod | fingolimod
|
||
| Risk of Acute Myocardial Infarction and Stroke among Carbidopa/Levodopa, Entacapone, and Carbidopa/Levodopa/Entacapone Users | carbidopa/levodopa, carbidopa/levodopa/entacapone (Stalevo), entacapone
|
||
| Prevalence and Incident Use of Promethazine | promethazine, promethazine/codeine, promethazine/phenylephrine/codeine
|
||
| Use of Clonazepam | clonazepam
|
||
| Diagnosis of Agranulocytosis Following New Use of Anti-epileptic Drugs, Clozapine, and Olanzapine | carbamazepine, clozapine, lamotrigine, levetiracetam, ofatumumab, olanzapine, topiramate
|
agranulocytosis |
|
| Counts and Prevalence of Alendronate, Risedronate, Ibandronate, and Zolendronate | alendronate sodium, alendronate sodium/vitamin d3, bandronate sodium, calcitonin salmon, calcitonin, salmon, synthetic, denosumab, ibandronate sodium, raloxifene HCL, risedronate sodium, risedronate sodium/calcium carbonate, teriparatide, zoledronic acid, zoledronic acid reclast, zoledronic acid/mannitol and water, zoledroniccid reclast, zoledroniccid zometa
|
||
| Counts and Prevalence of Linezolid and Vancomycin | linezolid, vancomycin
|
||
| Use of Atrial Fibrillation Drugs | dofetilide, sotalol HCL
|
||
| Incident Use of Hepatitis C Virus (HCV) Drugs | boceprevir, ledipasivir/sofosbuvir, simeprevir sodium, sofosbuvir, telaprevir
|
||
| Concomitancy and Indications for Idelalisib Use | bendamustine, bortezomib, chlorambucil, cyclophosphamide, doxorubicin, ibritumomab, ibrutinib, idelalisib, lenalidomide, obinutuzumab, ofatumumab, prednisone, rituximab, vincristine
|
||
| Prevalent and Incident Use of Generic Name Kinase Inhibitors | afatinib dimaleate, axitinib, bortezomib, cabozantinib s-malate, carfilzomib, ceritinib, crizotinib, dabrafenib mesylate, dasatinib, erlotinib HCL, everolimus, gefitinib, ibrutinib, idelalisib, imatinib mesylate, lapatinib ditosylate, nilotinib HCL, pazopanib HCL, ponatinib HCL, regorafenib, ruxolitinib phosphate, sorafenib tosylate, sunitinib malate, trametinib dimethyl sulfoxide, vandetanib, vemurafenib
|
||
| Incident Use of Rivaroxaban | rivaroxaban
|
||
| Selected Medications and Death, with Linkage of Mini-Sentinel Distributed Database with NDI+ | amiodarone, amitriptyline, amoxapine, amoxicillin, amoxicillin with clavulanate, azithromycin, cephalexin, ciprofloxacin, citalopram, clarithromycin, clindamycin, clomipramine, desipramine, desvenlafaxine, dofetilide, doxepin, dronedarone, duloxetine, erythromycin, escitalopram, flecainide, fluoxetine, fluvoxamine, gemifloxacin, imipramine, levofloxacin, levomilnacipran, maprotiline, mirtazapine, moxifloxacin, nefazodone, norfloxacin, nortriptyline, ofloxacin, paroxetine, penicillin V, propafenone, protriptyline, sertraline, sotalol, telithromycin, trazodone, trimethoprim-sulfamethoxazole, trimipramine, venlafaxine, vilazodone, vortioxetine
|
sudden cardiac death |
|
| Combined Oral Contraceptives Containing Ethinyl Estradiol and Levonorgestrel and Venous Thromboembolism | combined oral contraceptive (COC)
|
venous thromboembolism (VTE) |
|
| Venous Thromboembolism Following Continuous or Extended Cycle Contraceptive Use: A Propensity Score Matched Analysis | combined oral contraceptive (COC)
|
venous thromboembolism (VTE) |
|
| Counts, Prevalence, and Incidence of Intravenous (IV) Iron Products | ferumoxytol, iron dextran complex, iron sucrose complex, sodium ferric gluconate complex
|
||
| Exposure to Intravenous (IV) Iron Procedures and Anaphylaxis and Epinephrine Events | intravenous (IV) iron
|
anaphylaxis , epinephrine event |
|
| Rhabdomyolysis and/or Creatine Kinase Laboratory Results Following New Use of Statins or Angiotensin-Converting Enzyme Inhibitors | angiotensin-converting enzyme (ACE) inhibitor, statin
|
creatine kinase laboratory result , rhabdomyolysis |
|
| Use of Tyrosine Kinase Inhibitors (TKIs) | axitinib, pazopanib, sorafenib, sunitinib, tyrosine kinase inhibitor
|
||
| Length of Follow-up Time for New Users of Immunosuppressive Drugs | adalimumab, alemtuzumab, certolizumab, dalfampridine, dimethyl fumarate, etanercept, fingolimod, glatiramer acetate, golimumab, infliximab, interferon beta-1A, interferon beta-1B, mitoxantrone, natalizumab, pegylated interferon beta-1A, teriflunomide, ustekinumab
|
||
| Prevalent and Incident Dispensings of Ranolazine | ranolazine
|
||
| Boceprevir, Ledipasivir/Sofosbuvir, Simeprevir Sodium, Sofosbuvir, and Telaprevir Use | boceprevir, ledipasivir/sofosbuvir, simeprevir sodium, sofosbuvir, telaprevir
|
hepatitis C |
|
| Concomitant Use of Opioid Analgesics and Cytochrome P450 (CYP) Inhibitors and Inducers | CYP inducer, CYP inhibitor, oxycodone, oxymorphone
|
||
| Prevalent and Incident Use of SGLT2 Inhibitors | canagliflozin, canagliflozin/metformin HCl, dapagliflozin propanediol, dapagliflozin/metformin HCl, empagliflozin, empagliflozin/linagliptin
|
||
| Metabolic Effects of Second Generation Antipsychotics in Youth, Subprojects 1, 2, and 3 | aripiprazole, olanzapine, quetiapine, risperidone, second generation antipsychotic (SGA)
|
metabolic syndrome , type 2 diabetes mellitus , weight gain |
|
| PROMPT: Rivaroxaban Surveillance | rivaroxaban, warfarin
|
gastrointestinal (GI) bleed , intracranial hemorrhage , ischemic stroke |
|
| Antiepileptic Drug (AED) Injection Procedure Codes | anti-epileptic drug (AED)
|
||
| Counts of Commonly Used Angiostensin-Converting Enzyme (ACE) Inhibitors and Beta Blockers | angiotensin-converting enzyme (ACE) inhibitor, beta blocker
|
||
| Drug and Medical Enrollment Counts | |||
| A Protocol for Assessment of Dabigatran and Selected Safety Outcomes | dabigatran, warfarin
|
intracranial hemorrhage , ischemic stroke , major extracranial hemorrhage |
|
| Use of Tumor Necrosis Factor (TNF) Blocker Drugs | tumor necrosis factor (TNF) blocker
|
||
| Characterization of Pediatric Medical Conditions: Respiratory Syncytial Virus (RSV) Associated Illness | respiratory syncytial virus (RSV) |
||
| Molecularly Targeted Anti-Cancer Therapies | axitinib, bicalutamide, crizoatinib, dasatinib, erlotinib HCL, everolimus, gefitinib, imatinib mesylate, lapatinib ditosylate, nilotinib HCL, pazopanib HCL, ruxolitinib phosphate, sorafenib tosylate, sunitinib malate, tamoxifen citrate, vandetanib, vemurafenib, vismodegib
|
||
| Stroke Diagnosis Codes | stroke |
||
| Length of Enrollment in Pediatric Population | |||
| Prevalent and Incident Use of Isotretinoin | isotretinoin
|
||
| Occurrence of Selected Generic Drugs 13 | amlodipine besylate, efalizumab, ibandronate sodium, lamotrigine, leflunomide, maraviroc, metoclopramide HCL, nitrofurantoin, nitrofurantoin macrocrystal, nitrofurantoin monohyd/m-crystal, propylthiouracil, quinine, quinine sulfate, ramipril, rosiglitazone maleate, sibutramine HCL m-hydrate, tadalafil, varenicline tartrate
|
||
| Clostridium Difficile Prevalence and Vancomycin, Fidaxomicin, and Tocilizumab Use | fidaxomicin, tocilizumab, vancomycin
|
clostridium difficile |
|
| Use of Dronedarone HCL | dronedarone HCL
|
||
| Incident and Prevalent Dispensings of Mirabegron | mirabegron
|
||
| Use of Ospemifene, Boceprevir, and Telaprevir | boceprevir, ospemifene, telaprevir
|
||
| Prevalent and Incident Use of Testosterone Products | testosterone
|
||
| Top 100 Procedures and Diagnoses 30 Days Surrounding Incident Warfarin Use | warfarin
|
||
| Anti-Tumor Necrosis Factor (TNF) Utilization Among Pregnant Women | adalimumab, certolizumab, etanercept, golimumab, infliximab, tumor necrosis factor (TNF) alpha inhibitor
|
||
| Prevalent and Incident Use of Romiplostim | romiplostim
|
||
| Suicide Diagnoses | suicide |
||
| Incident and Prevalent Use of Generic Drugs for Overactive Bladder | darifenacin hydrobromide, fesoterodine fumarate, oxybutynin chloride, solifenacin succinate, tolterodine tartrate, trospium chloride
|
||
| Use of Cancer Drugs | crizoatinib, erlotinib HCL, ipilimumab, nivolumab, pembrolizumab
|
||
| Antipsychotic Use and Dementia Diagnoses | antipsychotic
|
dementia |
|
| Genetic Testing Procedures | |||
| Atrial Fibrillation Prevalence | atrial fibrillation , atrial flutter |
||
| Mycophenolate Dispensings and Procedures | mycophenolate mofetil, mycophenolate mofetil HCL, mycophenolate sodium
|
||
| Mycophenolate Dispensings and Procedures (by Quarter) | mycophenolate mofetil, mycophenolate mofetil HCL, mycophenolate sodium
|
||
| Niacin and Fenofibrate Use and Outcomes with Propensity Score Matching | extended-release (ER) niacin, fenofibrate
|
gastrointestinal (GI) bleed , intracranial hemorrhage , ischemic stroke |
|
| Stroke Following Typical or Atypical Antipsychotic Use in Non-Elderly Patients: A Propensity Score Matched Analysis | antipsychotic
|
stroke |
|
| Stroke Following Atypical Antipsychotic or Z-Hypnotic Use in Patients with Prior Use of Selective Serotonin Reuptake Inhibitors (SSRIs): A Propensity Score Matched Analysis | aripiprazole, fluoxetine, olanzapine, quetiapine, risperidone
|
stroke |
|
| Antipsychotics and Stroke | aripiprazole, atypical antipsychotic, haloperidol, olanzapine, olanzapine/fluoxetine, quetiapine, risperidone, selective serotonin reuptake inhibitor (SSRI), typical antipsychotic
|
intracranial hemorrhage , ischemic stroke |
|
| Sodium/Glucose Cotransporter (SGLT2) Inhibitors- Type 1 and Type 2 Diabetes Cohort Identification | dipeptidyl peptidase-4 (DPP-4) inhibitor, sodium-glucose cotransporter-2 (SGLT-2) inhibitor, sulfonylurea
|
diabetes , type 1 diabetes mellitus , type 2 diabetes mellitus |
|
| Niacin and Niacin Combination Products, Fenofibrates, and Omega-3 Products | fenofibrate, niacin, niacin/lovastatin, niacin/simvastatin, omega-3 product
|
||
| Alosetron Use | alosetron HCL
|
||
| Mirabegron Use | mirabegron
|
||
| Pegylated Products Use | certolizumab pegol, methoxy peg-epoetin beta, pegademase bovine, peginterferon beta-1a, pegloticase, pegvisomant
|
||
| Pegylated Products Follow-Up Request | |||
| New Molecular Entities | abiraterone acetate, aclidinium bromide, ado-trastuzumab emtansine, afatinib dimaleate, albiglutide, alcaftadine, alectinib HCL, alglucosidase alfa, alirocumab, alogliptin benzoate, apixaban, apremilast, aripiprazole, aripiprazole lauroxil, asfotase alfa, asparaginase, avanafil, axitinib, azilsartan medoxomil, bazedoxifene, bedaquiline fumarate, belatacept, belimumab, belinostat, blinatumomab, boceprevir, bosutinib, brexpiprazole, cabazitaxel, cabozantinib, canagliflozin, cangrelor tetrasodium, carfilzomib, carglumic acid, cariprazine HCL, ceftaroline fosamil acetate, ceftazidime/avibactam, ceftolozane, ceritinib, cholic acid, clobazam, cobicistat, cobimetinib fumarate, collagenase clostridium histolyticum, crofelemer, dabigatran etexilate mesylate, dabrafenib mesylate, daclatasvir dihydrochloride, dalbavancin HCL, dalfampridine, dapagliflozin propanediol, daratumumab, deferiprone, denosumab, deoxycholic acid, dimethyl fumarate, dinutuximab, dolutegravir sodium, droxidopa, dulaglutide, edoxaban tosylate, efinaconazole, eliglustat tartrate, elosulfase alfa, elotuzumab, eluxadoline, elvitegravir, elvitegravir/cobicistat/emtricitabine/tenofovir, empagliflozin, enzalutamide, eribulin mesylate, eslicarbazepine acetate, estradiol valerate/dienogest, estrogen, evolocumab, ezogabine, fidaxomicin, fingolimod HCL, flibanserin, florbetapir f-18, fluconazole, flutemetamol f-18, gabapentin enacarbil, gadobutrol, gadoterate meglumine, glucarpidase, ibrutinib, icatibant acetate, idarucizumab, idelalisib, incobotulinumtoxina, indacterol maleate, ingenol mebutate, insulin degludec, ioflupane i-123, ipilimumab, isavuconazonium sulfate, ivabradine HCL, ivacaftor, ixazomib citrate, ledipasvir, lenvatinib mesylate, linaclotide, linagliptin, liraglutide, lomitapide mesylate, lorcaserin HCl, lucinactant, luliconazole, lumacaftor/ivacaftor, lurasidone HCL, macitentan, mepolizumab, metreleptin, miltefosine, mipomersen sodium, naloxegol oxalate, necitumumab, netupitant, nintedanib esylate, nivolumab, obinutuzumab, ocriplasmin, olaparib, olodaterol HCL, omacetaxine mepesuccinate, ombitasvir, oritavancin diphosphate, osimertinib mesylate, ospemifene, palbociclib, palonosetron HCL, panobinostat lactate, parathyroid hormone, paritaprevir, pasireotide diaspartate, patiromer calcium sorbitex, peginterferon beta-1a, pegloticase, pembrolizumab, peramivir, pirfenidone, pitavastatin, polidocanol, pomalidomide, radium-223 dichloride, ramucirumab, rilpivirine HCL, riociguat, rivaroxaban, roflumilast, rolapitant HCL, ruxolitinib phosphate, sacubitril/valsartan, sebelipase alfa, secukinumab, selexipag, siltuximab, simeprevir sodium, sofosbuvir, sonidegib phosphate, spinosad, sugammadex sodium, sulfur hexafluoride microsphere, suvorexant, tasimelteon, tazobactam, tedizolid phosphate, teduglutide, telaprevir, tenofovir disoproxil fumarate, teriflunomide, tesamorelin acetate, ticagrelor, tocilizumab, tofacitinib citrate, trabectedin, trametinib dimethyl sulfoxide, trifluridine/tipiracil HCL, ulipristal acetate, umeclidinium, uridine, vandetanib, vedolizumab, velaglucerase alfa, vemurafenib, vilanterol, vilazodone HCL, vismodegib, vorapaxar sulfate, vortioxetine hydrobromide, ziv-aflibercept
|
||
| Indications of Use Among Oral Antifungal Drug Users | fluconazole, griseofulvin, itraconazole, ketoconazole, terbinafine
|
||
| Actemra (Tocilizumab) Utilization Among Pregnant Women | Actemra, tocilizumab
|
juvenile rheumatoid arthritis , rheumatoid arthritis |
|
| Anti-epileptic Drugs and Angioedema | lacosamide, lamotrigine, levetiracetam, oxcarbazepine, phenytoin
|
angioedema |
|
| Drug Use Following Genetic Testing Among Patients with Cancer | afatinib dimaleate, BCR-ABL, bosutinib, BRAF, BRCA, cetuximab, cobimetinib fumarate, dabrafenib mesylate, dasatinib, erlotinib HCL, estimated glomerular filtration rate (eGFR), gefitinib, imatinib mesylate, KRAS, nilotinib HCL, olaparib, osimertinib mesylate, panitumumab, ponatinib HCL, trametinib dimethyl sulfoxide, vemurafenib
|
cancer |
|
| Multiple Births and Preterm Deliveries | preterm delivery |
||
| Influenza Antiviral Drug Use 2010-2015 | oseltamivir, zanamivir
|
||
| Prevalent Dispensings of Ticagrelor (Brilinta) and Vortioxetine Hydrobromide (Brintellix) | Brilinta, Brintellix, ticagrelor, vortioxetine hydrobromide
|
||
| Attention Deficit Hyperactivity Disorder (ADHD) Medications and Heart Failure | amphetamine, methylphenidate, Strattera
|
heart failure or cardiomyopathy |
|
| PROMPT: Mirabegron Surveillance | mirabegron, oxybutynin
|
acute myocardial infarction (AMI) , stroke |
|
| Dronedarone and Electrocardiograms | dronedarone
|
electrocardiogram |
|
| Parenteral Iron and Anaphylactoid Reactions | parenteral iron (IV iron)
|
anaphylactoid reaction |
|
| Dabigatran and Warfarin Use Among Members with Atrial Fibrillation and Other Pre-Existing Conditions | dabigatran, warfarin
|
||
| MRI and GBCA Procedures | |||
| Hysterectomy Procedures Among Females | hysterectomy , morcellation , uterine fibroid |
||
| Most Frequent Generic Dispensings Among Members Aged 65+ | |||
| Incident Testosterone Indication Diagnoses and Testosterone Use | testosterone
|
||
| Hypogonadism and Testosterone Use | testosterone
|
hypogonadism |
|
| Incident Testosterone Use | testosterone
|
||
| Immunoglobulin Products and Hemolysis | immunoglobulin (Ig)
|
hemolysis |
|
| New Use of Statins and Rhabdomyolysis | atorvastatin, fluvastatin, lovastatin, pitavastatin, pravastatin, rosuvastatin, simvastatin, statin
|
rhabdomyolysis |
|
| Epidural Steroid Use | epidural steroid
|
||
| Serum Creatinine Procedures and Labs | |||
| Isotretinoin and Long-term Antibiotic Use and Multiple Sclerosis | abacavir, doxycycline, erythromycin, isotretinoin, lamivudine, long-term antibiotic, minocycline, zidovudine
|
multiple sclerosis |
|
| Laparoscopic Hysterectomy With and Without Robotic Assistance and Adverse Outcomes | laparoscopic hysterectomy
|
intraoperative complication , medical complication , surgical site complication |
|
| New Use of Dabigatran or Warfarin and Gastrointestinal Hemorrhage or Intracerebral Hemorrhage Events | dabigatran, warfarin
|
gastrointestinal hemorrhage , intracerebral hemorrhage (ICH) |
|
| New Use of Anti-Epileptic Drugs and Agranulocytosis | anti-epileptic drug (AED), carbamazepine, lamotrigine, levetiracetam, topiramate
|
absolute neutrophil count (ANC) , agranulocytosis |
|
| Omalizumab or Montelukast Use Among Individuals with Asthma and Acute Myocardial Infarction, Stroke, Intracranial Hemorrhage, or Pulmonary Embolism | omalizumab
|
acute myocardial infarction (AMI) , intracranial hemorrhage , stroke |
|
| IVIg Product Use and Hemolysis Events | flebogamma, Gammagard, Gammaplex, Gamunex, intravenous immunoglobulin (IVIg), Octagam, Privigen
|
||
| Incident Use of Testosterone Products Among All Members and Members with Pre-Existing Testosterone Use | Androgel, Axiron, Fortesta, intramuscular testosterone, methyltestosterone, Striant, Testim, testosterone, testosterone cypionate, testosterone enanthate, testosterone pellet, testosterone propionate, testosterone suspension, transdermal testosterone
|
||
| Concomitant Use of Niacin and Statins and Concomitant Use of Fenofibrates and Statins | fenofibrate, niacin, statin
|
||
| Anticoagulant Use Among Members with Atrial Fibrillation and Various Pre-Existing Exlusions | anticoagulant, dabigatran, warfarin
|
||
| Anticoagulant Use Among Members with Pre-Existing Atrial Fibrillation and Various Pre-Existing Exclusions | anticoagulant, dabigatran, warfarin
|
||
| Antidepressant Use and Bleeding Events | antidepressant, selective serotonin reuptake inhibitor (SSRI), serotonin-norepinephrine reuptake inhibitor (SNRI), tricyclic
|
bleeding event , gastrointestinal hemorrhage , intracerebral hemorrhage (ICH) |
|
| Dabigatran Uptake and Persistence | dabigatran
|
||
| Incident Antipsychotic Use | antipsychotic, aripiprazole, asenapine, clozapine, iloperidone, lurasidone, olanzapine, paliperidone, quetiapine, risperidone, ziprasidone
|
||
| Indications of Intravenous Immunoglobulin Use | intravenous immunoglobulin (IVIg)
|
||
| Anticoagulants and Bleeding Events | anticoagulant, dabigatran, warfarin
|
bleeding event |
|
| Anticoagulant Use Among Patients with Atrial Fibrillation | anticoagulant, dabigatran, oral formulation of apixaban, rivaroxaban, warfarin
|
||
| Drug Use Among Pregnant Women with Live Births | angiotensin-converting enzyme (ACE) inhibitor, anticonvulsant, dabigatran, lisinopril, methotrexate, mycophenolate mofetil, paroxetine, ribavirin, selective serotonin reuptake inhibitor (SSRI), simvastatin, sodium valproate, statin, valproic acid, warfarin
|
||
| Anti-Diabetes Drugs and Acute Myocardial Infarction, Hospitalized Heart Failure | anti-diabetic agent (ADA), dipeptidyl peptidase-4 (DPP-4) inhibitor, glimepiride, glipizide, glyburide, hypoglycemic drug, long-acting insulin, pioglitazone, saxagliptin, sitagliptin, sulfonylurea, thiazolidinedione
|
acute myocardial infarction (AMI) , heart failure |
|
| Select Bisphosphonates and Select Outcomes of Interest | biphosphonate
|
esophageal cancer , fracture , hip fracture , non-vertebral fracture , osteonecrosis of the jaw |
|
| Anaphylaxis Events Following Incident Vaccine Exposure Among Members with a Pre-Existing Condition of Milk Allergy | diphtheria, tetanus, acellular pertussis (DTaP) vaccine, diphtheria, tetanus, acellular pertussis (DTaP)-haemophilus influenzae type B (HIB) vaccine, diphtheria, tetanus, acellular pertussis (DTaP)-haemophilus influenzae type B (HIB)-inactivated polio vaccine (IPV), diphtheria, tetanus, acellular pertussis (DTaP)-hepatitis B (Hep B)-inactivated polio vaccine (IPV), diphtheria, tetanus, acellular pertussis (DTaP)-inactivated polio vaccine (IPV), tetanus, diphtheria, pertussis (Tdap) vaccine
|
anaphylactic shock |
|
| Gastrointestinal Disorders | entercolitis , gastrointestinal disorder , ileocolitis , procitis , proctosigmoiditis , pseudopolyposis , regional enteritis , ulcerative colitis |
||
| Injection Omalizumab Procedure Codes | omalizumab
|
||
| Omalizumab Use | omalizumab
|
||
| Prevalent and Incident Use of Pramipexole | pramipexole
|
||
| Hypoglycemic Events Following Use of Anti-Diabetic Agents (ADAs) | anti-diabetic agent (ADA), chlorpropamide, glimepiride, glipizide, glipizide/metformin, glyburide, glyburide/metformin, insulin, metformin, pioglitazone, pioglitazone/metformin, rosiglitazone maleate, rosiglitazone/metformin, tolazamide
|
hypoglycemia |
|
| Omalizumab and Montelukast Use | montelukast, omalizumab
|
||
| Progressive Multifocal Leukoencephalapathy | progressive multifocal leukoencephalopathy (PML) |
||
| Methotrexate and Tofacitinib Use | methotrexate, methotrexate sodium, methotrexate sodium, preservative free, tofacitinib citrate
|
||
| Incident and Prevalent Use of Alvimopan, Naltrexone, and Methylnaltrexone | alvimopan, methylnaltrexone bromide, morphine sulfate/naltrexone, naltrexone, naltrexone HCL, naltrexone microsphere
|
||
| Procedure Codes Related to Memory Gel Breast Implants | breast implant
|
||
| Opioid Medication Use | Buprenex, Butrans, generic injectable buprenorphine, generic oral buprenorphine, generic powder buprenorphine, opioid, Suboxone, Subutex
|
||
| Buprenorphine Product Use | buprenorphine
|
||
| CPAX Aneurysm Procedure Codes | CPAX aneurysm , emboli detection , intravenous microbubble injection , surgery of intracranial aneurysm , transcranial doppler study |
||
| Lap-band Diagnosis Codes | gastric lap band
|
bariatric surgery , gastric band procedure |
|
| Ascension Metacarpophalangeal Procedures | arthroplasty metacarpophalangeal interphalangeal joint , arthrotomy for removal of prosthesis , division of joint |
||
| CPAX Aneurysm Diagnoses | CPAX aneurysm , aneurysm , arthropod-borne hemorrhagic fever , cerebral aneurysm nonruptured , intracerebral hemorrhage (ICH) , mosquito-borne viral encephalitis , subarcahnoid hemorrhage |
||
| Activa Tremor Control Procedures | Activa Tremor Control |
||
| Ascension Metacarpophalangeal Diagnoses | Ascension metacarpophalangeal (MCP) , arthritis , diffuse disease of connective tissue , osteoarthritis , sprain and strain of metacarpophalangeal of hand , traumatic arthropathy |
||
| Activa Tremor Control Diagnoses | neuropacemaker
|
Activa Tremor Control , essential tremor , other specified forms of tremor , paralysis agitans |
|
| Dialysis HCPCS Procedure Codes | dialysis , end-stage renal disease (ESRD) , kidney failure |
||
| Dialysis ICD9 Diagnosis Codes | dialysis , end-stage renal disease (ESRD) , kidney failure |
||
| Dialysis ICD9 Procedure Codes | dialysis , end-stage renal disease (ESRD) , kidney failure |
||
| Anti-Infective Agents Use 2 | anti-infective agent
|
||
| Cardiovascular Therapy Agent Use 2 | acebutolol HCL, cardiovascular therapy agent
|
||
| Gastrointestinal Therapy Agents Use 2 | gastrointestinal therapy agent
|
||
| Antiepileptic Drugs (AEDs) and Kidney Stones 2 | anti-epileptic drug (AED), carbamazepine, gabapentin, lamotrigine, levetiracetam, oxcarbazepine, phenytoin, topiramate, valproic acid, zonisamide
|
kidney stone |
|
| Infectious Disease Diagnoses | Chagas disease , anthrax , ascariasis , hepatitis , hepatitis C , hookworm , influenza , leishmaniasis , malaria , methicillin-resistant Staphylococcus aureus (MRSA) , plague , schistosomiasis , trichuriasis , tuberculosis (TB) , tularemia |
||
| Occurrence of Selected Generic Drugs 12 | |||
| Analgesic Use 3 | analgesic
|
||
| Diabetes Diagnoses and Occurrence of Laboratory Results | |||
| Anti-D, Dexamethasone, Prednisone, Romiplostim and Hemolysis | anti-D, dexamethasone, prednisone, romiplostim
|
hemolysis |
|
| Immune Globulin Use | immune globulin, gamma (IgG), immune globulin, gamma (IgG)/maltose, immune globulin, gamma caprylate (IgG)
|
||
| Injection Gammagard Use | Gammagard
|
||
| Hemorrhagic Disorder Diagnoses | acquired hemophilia , hemorrhagic disorder |
||
| Occurrence of Kidney Stones | anti-diabetic agent (ADA)
|
kidney stone |
|
| Hemodialysis Procedures | hemodialysis |
||
| Enoxaparin Sodium Use | enoxaparin sodium
|
||
| Injection Enoxaparin Sodium Use | enoxaparin sodium
|
||
| Acute Kidney Failure Diagnoses | acute kidney failure |
||
| Occurrence of Selected Dental HCPCS Codes | |||
| Nursing Home Facility HCPCS Codes | |||
| Prevalent and Incident Use of Acetazolamide | acetazolamide
|
||
| Long Acting Beta2-Agonists (LABA) Policies and Drug Utilization Patterns | long-acting beta2 agonist (LABA)
|
change in drug utilization patterns |
|
| Anti-Seizure Medication Use | carbamazepine, ethosuxamide, felbamate, gabapentin, lamotrigine, levetiracetam, oxcarbazepine, phentermine HCl, phentermine resin, phenytoin, phenytoin sodium, phenytoin sodium extended, pregabalin, tiagabine HCL, topiramate, valproic acid, zonisamide
|
||
| Occurrence of Selected Generic Drugs 11 | benzyl alcohol, boceprevir, dabigatran etexilate mesylate, eltrombopag olamine, febuxostat, pitavastatin calcium, Pradaxa, rivaroxaban, telaprevir, vigabatrin
|
||
| Multiple Sclerosis Medication Use | fingolimod HCL, glatiramer acetate, interferon beta-1A, interferon beta-1A/albumin, interferon beta-1B, mitoxantrone HCL, natalizumab
|
||
| Multiple Sclerosis Medication Injections | injection glatiramer acetate, injection interferon beta-1A, injection interferon beta-1A, injection interferon beta-1B, injection mitoxantrone HCL, injection natalizumab
|
||
| Prevalent and Incident Use of Quinine Sulfate | quinine sulfate
|
||
| Quinine Sulfate, Diltiazem and Selected Thrombotic Events | diltiazem, quinine sulfate
|
hemolytic-uremic syndrome , immune thrombocytopenic purpura , other secondary thrombocytopenia , thrombotic microangiopathy , unspecified thrombocytopenia |
|
| Antiepileptic Drugs (AEDs) and Kidney Stones | anti-epileptic drug (AED), carbamazepine, gabapentin, lamotrigine, levetiracetam, oxcarbazepine, phenytoin, topiramate, zonisamide
|
kidney stone |
|
| Chronic Kidney Disease Diagnoses | chronic kidney disease (CKD) |
||
| Nursing Home HCPCS Codes | |||
| Oral Antifungal Use | fluconazole, itraconazole, ketoconazole, posaconazole, terbinafine, voriconazole
|
||
| Occurrence of Selected Generic Drugs 10 | allopurinol, diclofenac, isoniazid, lapatinib, telithromycin, ticlopidine
|
||
| Antiepileptic Drug Use | acetazolamide, carbamazepine, clobazam, clonazepam, diazepam, ethosuxamide, ezogabine, felbamate, gabapentin, lacosamide, lamotrigine, levetiracetam, lorazepam, oxcarbazepine, phenobarbital, phenytoin, pregabalin, primidone, rufinamide, tiagabine, topiramate, valproic acid, vigabatrin, zonisamide
|
||
| Propylthiouracil and Methimazole Use 2 | methimazole, propylthiouracil
|
||
| Unspecified Anterior Pituitary Hyperfunction and Hypertrophy of the Breast Diagnoses | anterior pituitary hyperfunction , hypertrophy |
||
| HIV and HBV Infection Diagnoses | hepatitis B virus (HBV) , human immunodeficiency virus (HIV) |
||
| Bupropion HCL Sustained Release HCPCS Codes | bupropion HCL sustained release tablet
|
||
| Occurrence of Selected Generic Drugs 9 | ezetimibe/simvastatin, lisinopril, lisinopril/dietary sup. Cmb10, lisinopril/hydrochlorothiazide, methotrexate, methotrexate sodium, mycophenolate mofetil, mycophenolate sodium, niacin/simvastatin, paroxetine HCL, paroxetine mesylate, ribavirin, ribavirin/interferon alfa-2B, simvastatin, valproic acid, warfarin sodium
|
||
| Cardiovascular Therapy Agents Use | acebutolol HCL, aliskiren hemifumarate, ambrisentan, amlodipine besylate, atenolol, betaxolol HCL, bosentan, captopril, carvedilol, conivaptan HCL, diltiazem HCL, eprosartan mesylate, indapamide, labetalol HCL, lisinopril, metoprolol succinate, metoprolol tartrate, metoprolol/hydrochlorothiazide, nadolol, nimodipine, perindopril erbumine, propafenone HCL, trandolapril, triamterene
|
||
| Analgesic Use 2 | acetaminophen with codeine, aspirin/codeine phosphate, codeine phosphate, codeine sulfate, fentanyl citrate, methadone HCL, morphine sulfate, oxycodone HCL, oxymorphone HCL, sulindac, tramadol HCL
|
||
| Anti-Infective Agents Use | acyclovir, acyclovir sodium, atovaquone, doxycycline calcium, doxycycline hyclate, nitazoxanide, norfloxacin, telithromycin, tenofovir disoproxil fumarate
|
||
| Gastrointestinal Therapy Agents Use | aprepitant, cimetidine, dexlansoprazole, dicyclomine HCL, fosaprepitant dimeglumine, lubiprostone, mesalamine, nizatidine, sucralfate
|
||
| Occurrence of Selected Generic Drugs 8 | alosetron HCL, alvimopan, ambrisentan, bosentan, buprenorphine HCL, bupropion HCL, isotretinoin, lenalidomide, metoclopramide HCL, naloxone HCL, nilotinib HCL, propoxyphene HCL, propoxyphene HCL/acetaminophen, propoxyphene HCL/ASA/caffeine, ribavirin/interferon alfa-2B, rosiglitazone/glimepiride, rosiglitazone/metformin HCL, sacrosidase, sibutramine HCL, thalidomide, varenicline tartrate
|
||
| Occurrence of Selected Generic Drugs 7 | albuterol, albuterol sulfate, alvimopan, calcium acetate, chlorambucil, cyclosporine, cyclosporine modified, levalbuterol HCL, levalbuterol tartrate, lindane, phytonadione, solifenacin succinate, tretinoin, vorinostat
|
||
| Parkinson’s Disease Medication Use | carbidopa, combination product of carbidopa, entacapone, levodopa, levodopa and entacapone (Stalevo)
|
||
| Oxicam NSAIDs, Modafinil/Armodafinil, Sulfamothoxazole and Severe Cutaneous Adverse Reaction (SCAR) Events | modafinil, modafinil/armodafinil, oxicam, sulfamothoxazole
|
severe cutaneous adverse reaction (SCAR) |
|
| Angiotensin Receptor Blockers (ARBs), Hydrochlorothiazide, Atenolol, Amlodipine Use and Celiac Disease | amlodipine, angiotensin II receptor blocker (ARB), atenolol, candesartan, eprosartan, hydrochlorothiazide (HCTZ), irbesartan, losartan, olmesartan, telmisartan, valsartan
|
celiac disease |
|
| Occurrence of Selected Pediatric Drugs 1 | acetaminophen with codeine, acyclovir, albuterol, nizatidine, sucralfate
|
||
| Vascular Endothelial Growth Factor (VEGF) Inhibitor Prevalent and Incident Use | bevacizumab, sorafenib, sunitinib, thalidomide, vascular endothelial growth factor (VEGF) inhibitor
|
||
| Dabigatran, Rivaroxaban, and Warfarin Use | dabigatran, rivaroxaban, warfarin
|
||
| Dabigatran, Warfarin and GI Bleed, Intracerebral Hemorrhage | dabigatran, warfarin
|
gastrointestinal hemorrhage , intracerebral hemorrhage (ICH) , serious bleeding |
|
| Warfarin and GI Bleed, Intracerebral Hemorrhage | warfarin
|
gastrointestinal hemorrhage , intracerebral hemorrhage (ICH) , serious bleeding |
|
| Dabigatran (Pradaxa), Warfarin and Gastrointestinal Bleed, Intracerebral Hemorrhage | anticoagulant, blood thinner, Coumadin, dabigatran, Pradaxa, warfarin
|
gastrointestinal hemorrhage , intracerebral hemorrhage (ICH) , serious bleeding |
|
| Selgiline Use | selgiline
|
||
| Lindane Use Modular Program | lindane
|
||
| Natalizumab, Efalizumab, and Progressive Multifocal Leukoencephalopathy (PML) | efalizumab, natalizumab
|
progressive multifocal leukoencephalopathy (PML) |
|
| Clopidogrel and Prasugrel Use | clopidogrel, prasugrel
|
||
| Bupropion and Naltrexone Use 2 | bupropion, naltrexone
|
||
| Bupropion and Naltrexone Use 1 | bupropion, naltrexone
|
||
| Duloxetine, Pregabalin, and Milnacipran Use 1 | duloxetine, milnacipran, pregabalin
|
||
| Duloxetine, Pregabalin, and Milnacipran Use 2 | duloxetine, milnacipran, pregabalin
|
||
| Amphotericin Use | amphotericin B, amphotericin B cholesteryl sulfate, amphotericin B lipid complex, amphotericin B liposome
|
||
| Isoniazid Use | isoniazid, rifampin/isoniazid, rifampin/isoniazid/pyrazinamid
|
||
| Boceprevir and Telaprevir Use | boceprevir, telaprevir
|
||
| Injection Amphotericin Procedures | injection amphotericin B, injection amphotericin B cholesteryl, injection amphotericin B lipid complex, injection amphotericin B lipid form, injection amphotericin B liposome
|
||
| Hip Implant Procedures and Diagnoses 2 | acetabular component , acquired hemophilia , femoral component , mechanical complication of internal orthopedic device implant and graft , partial hip replacement , total hip replacement |
||
| Occurrence of Selected Generic Drugs 6 | abacavir sulfate, didanosine, didanosine/calcium carb/mag, didanosine/sodium citrate, efavirenz/emtricitab/tenofovir, emtricitabine, emtricitabine/tenofovir, entecavir, lamivudine, stavudine, tenofovir disoproxil fumarate, zidovudine
|
||
| Nucleoside Reverse Transcriptase Inhibitor Procedures | didanosine, injection zidovudine, zidovudine oral
|
||
| Golimumab, Ustekinumab, and Dronedarone Hydrochloride Use (by Year) | dronedarone HCL, golimumab, ustekinumab
|
||
| Injection Ustekinumab and Injection Denosumab Procedures | injection ustekinumab
|
||
| Injection Natalizumab Procedures | injection natalizumab
|
||
| Occurrence of Selected Generic Drugs 4 | meloxicam, modafinil, piroxicam, sulfamethoxazole, trimethoprim-sulfamethoxazole
|
||
| Golimumab, Ustekinumab, and Dronedarone Hydrochloride Use (by Quarter) | dronedarone HCL, golimumab, ustekinumab
|
||
| Occurrence of Selected Generic Drugs 5 | alosetron HCL, ambrisentan, bosentan, buprenorphine HCL, eltrombopag olamine, fentanyl, hydromorphone HCL, isotretinoin, lenalidomide, mifepristone, oxycodone HCL, romiplostim, rosiglitazone maleate, rosiglitazone/glimepiride, rosiglitazone/metformin HCL, thalidomide, vigabatrin
|
||
| Natalizumab and Efalizumab Use | efalizumab, natalizumab
|
||
| Occurrence of Selected Generic Drugs 3 | alosetron HCL, ambrisentan, bosentan, buprenorphine HCL, fentanyl, hydromorphone HCL, isotretinoin, lenalidomide, methadone HCL, morphine sulfate, naloxone HCL, oxycodone HCL, rosiglitazone maleate, rosiglitazone/glimepiride, rosiglitazone/metformin HCL, thalidomide
|
||
| Drugs that Act on the Renin-Angiotensin-Aldosterone System (Angiotensin Converting Enzyme Inhibitors, Angiotensin Receptor Blockers, Aliskiren) and Angioedema | aliskiren, angiotensin II receptor blocker (ARB), angiotensin-converting enzyme (ACE) inhibitor
|
angioedema |
|
| Occurrence of Selected Generic Drugs 1 | azathioprine, azathioprine sodium, benzonatate, cabergoline, everolimus, lopinavir/ritonavir, mercaptopurine, ralegravir potassium, ribavirin, ribavirin A-2B, tenofovir disoproxil fumarate, tolvaptan, voriconazole
|
||
| Occurrence of Selected HCPCS Codes 1 | cabergoline oral, combination peginterferon and ribavirin, mercaptopurine oral, negative pressure wound therapy (NPWT)
|
||
| Infliximab Use | infliximab
|
||
| Injection Infliximab Procedures | injection infliximab
|
||
| Analgesics Use | analgesic
|
||
| Dalfampridine Use | dalfampridine
|
||
| Propylthiouracil and Methimazole Use | methimazole, propylthiouracil
|
||
| Occurrence of Selected Generic Drugs 2 | acitretin, acitretin/emollient combo. 26, ambrisentan, bosentan, busulfan, chlorambucil, clarithromycin, cyclophosphamide, dronedarone, finasteride, fluconazole, isotretinoin, lenalidomide, lisinopril, lisinopril/hydrochlorothiazide, lithium carbonate, lithium citrate, methimazole, methotrexate, methotrexate sodium, telavancin, thalidomide, topiramate, trastuzumab, valproic acid, warfarin
|
||
| Occurrence of Selected HCPCS Codes 2 | busulfan, chlorambucil, cyclophosphamide, finasteride, methotrexate, trastuzumab
|
||
| Regional Enteritis and Ulcerative Enterocolitis Diagnoses | Crohn's disease , regional enteritis , ulcerative enterocolitis |
||
| Arthritis Diagnoses | Felty's syndrome , arthritis , inflammatory polyarthropathy , juvenile chronic polyarthritis , rheumatoid arthritis |
||
| Lindane Use Summary Table | lindane
|
||
| Clozapine Use | clozapine
|
||
| Use of Vascular Endothelial Growth Factor (VEGF) Inhibitors | bevacizumab, sorafenib tosylate, sunitinib malate, thalidomide, vascular endothelial growth factor (VEGF) inhibitor
|
||
| Bone Resorption Inhibitor Use (by Drug Class) | bone resorption inhibitor
|
||
| VEGF and Bone Resorption Inhibitor Procedures | bone resorption inhibitor procedure , vascular endothelial growth factor (VEGF) |
||
| Negative Pressure Wound Therapy (NPWT) Procedures | negative pressure wound therapy (NPWT) |
||
| Milk Allergy Diagnoses | milk allergy |
||
| Hip Implant Procedures and Diagnoses | arthroplasty , hemiarthroplasty , hip implant , hip replacement |
||
| Progressive Multifocal Leukoencephalopathy Diagnoses | progressive multifocal leukoencephalopathy (PML) |
||
| Hyperlipidemia Diagnoses | hypercholesterolemia , hyperchylomicronemia , hyperglyceridemia , hyperlipidemia |
||
| Heart/Lung Resuscitation (CPR), Injection Diphenhydramine Hydrochloride (HCL), Injection Adrenaline Epinephrine Procedures | injection adrenaline epinephrine, injection diphenhydramine hydrochloride (HCL)
|
cardiopulmonary resuscitation (CPR) |
|
| Unspecified Allergic Reaction Diagnoses | unspecified allergic reaction |
||
| Cardiopulmonary Resuscitation (CPR) Not Otherwise Specified Procedures | cardiopulmonary resuscitation (CPR) |
||
| Asthma Diagnoses | asthma |
||
| Acute Myocardial Infarction Diagnoses | acute myocardial infarction (AMI) |
||
| Serious Cutaneous Adverse Reaction (SCAR) Diagnoses | severe cutaneous adverse reaction (SCAR) |
||
| Aseptic Necrosis of Bone Jaw Diagnoses | aseptic necrosis of bone jaw |
||
| Angiotensin II Receptor Blockers and Celiac Disease | angiotensin II receptor blocker (ARB), candesartan, eprosartan, irbesartan, losartan, olmesartan, telmisartan, valsartan
|
celiac disease |
|
| Smoking Cessation Drugs and Cardiovascular Outcomes | bupropion, varenicline
|
acute coronary occlusion without myocardial infarction , acute myocardial infarction (AMI) , cardiovascular outcome , intermediate coronary syndrome , unstable angina |